What is Adagrasib?
Adagrasib Tablet 200 mg is a breakthrough KRAS G12C inhibitor tablet developed to treat specific cancers, particularly those caused by the KRAS G12C mutation. This mutation is commonly observed in non-small cell lung cancer (NSCLC) and other solid tumors like colorectal or pancreatic cancers.
Unlike traditional treatments, Adagrasib Tablets work by precisely targeting and inhibiting the mutated KRAS G12C protein, which plays a crucial role in driving uncontrolled cancer cell growth. As a personalized cancer treatment, it offers a focused mechanism of action with reduced side effects compared to standard chemotherapy.
Key Benefits of Adagrasib Tablets
-
Precision Targeting: Blocks KRAS G12C mutation, helping slow tumor progression.
-
Oral Convenience: Available as an easy-to-use tablet format, suitable for at-home care.
-
Effective in Advanced Cancers: Especially useful for patients with advanced or metastatic NSCLC.
-
Well-Tolerated: Compared to chemotherapy, Adagrasib offers a more targeted therapy with fewer off-target effects.
 Medical Uses of Adagrasib
-
Non-Small Cell Lung Cancer (NSCLC): Approved for patients with KRAS G12C-mutated advanced or metastatic NSCLC.
-
Other Cancers: Being studied for colorectal cancer, pancreatic cancer, and other solid tumors with KRAS G12C mutation.
Possible Side Effects
While generally well-tolerated, some patients may experience:
-
Nausea and vomiting
-
Diarrhea
-
Fatigue
-
Loss of appetite
-
Elevated liver enzymes (monitoring advised)
-
Shortness of breath or persistent cough (especially in lung cancer patients)
Always consult your oncologist for monitoring and managing side effects properly.
Disclaimer
LetsMeds provides pharmaceutical information for educational and B2B purposes only. All medical decisions should be made under the guidance of a licensed healthcare professional. This page is intended for wholesalers, doctors, hospitals, clinics, pharmacies, and medical institutions. All trademarks and brand names mentioned belong to their respective owners.
